What are the recommended starting dose, titration schedule, contraindications, and monitoring parameters for doxepin when used for insomnia, pruritus, or depression?

Doxepin Prescribing Guide

For insomnia, start doxepin at 3-6 mg nightly; for depression, start at 75 mg daily; for pruritus, use 10 mg twice daily or topical formulations.

Insomnia (Primary Indication for Low-Dose Doxepin)

Starting Dose and Titration

The American Academy of Sleep Medicine recommends doxepin 3 mg or 6 mg for sleep maintenance insomnia 1. These ultra-low doses are FDA-approved specifically for insomnia and represent a fundamentally different use than traditional antidepressant dosing.

• Starting dose: 3 mg at bedtime 1
• Alternative dose: 6 mg at bedtime for patients requiring more robust effect 1
• Elderly/debilitated: Start with 3 mg 2
• No titration needed: These fixed low doses do not require upward adjustment 2
• Duration: Demonstrated sustained efficacy for 12 weeks in elderly patients without tolerance 2

Clinical Considerations for Insomnia

Low-dose doxepin (3-6 mg) works through selective H1-receptor antagonism at these doses, specifically targeting sleep maintenance and early morning awakenings rather than sleep onset 1, 2. The 2017 AASM guideline gives a weak recommendation for doxepin based on moderate-quality evidence showing benefits outweigh harms 1.

Key advantages at low doses:

• No next-day residual sedation 2, 3
• No anticholinergic effects at 3-6 mg 2
• No weight gain or appetite increase 2
• No evidence of tolerance over 12 weeks 2
• Improves wake time after sleep onset (WASO), total sleep time, and sleep efficiency in final quarter of night 2

Important caveat: Low-dose doxepin appears ineffective for insomnia in patients with major depressive disorder 4. In these patients, full antidepressant doses are required.

Depression

Starting Dose and Titration

For depression, start doxepin at 75 mg daily 5. This is 25-fold higher than insomnia dosing and should never be confused.

• Starting dose: 75 mg daily (can be divided or given once at bedtime) 5
• Titration: Increase by increments of the initial dose (75 mg) every 5-7 days until therapeutic benefit or significant side effects appear 6
• Usual therapeutic range: 75-150 mg/day 5
• Severe illness: May require up to 300 mg/day 5
• Maximum dose: 300 mg/day; exceeding this rarely provides additional benefit 5
• Mild symptoms: Some patients controlled on 25-50 mg/day 5

Once-Daily Dosing for Depression

The entire daily dose can be given at bedtime up to 150 mg 5. This approach:

• Maximizes sedative effects during sleep
• Minimizes daytime anticholinergic side effects
• Improves adherence
• May cause more morning sedation initially 7

The 150 mg capsule is intended for maintenance only, not treatment initiation 5.

Time to Effect

• Anti-anxiety effect: Apparent before antidepressant effect 5
• Optimal antidepressant effect: 2-3 weeks, with full therapeutic trial requiring 4-8 weeks 6, 5

Therapeutic Drug Monitoring

Despite widespread citation of a "therapeutic range" of 150-250 ng/mL (doxepin + desmethyldoxepin), this range lacks solid evidence 8. A 2001 analysis found:

• Only 9% of patients achieved 150-250 ng/mL on standard doses
• Mean concentration was 89±75 ng/mL on 143 mg/day
• No correlation between concentrations and clinical improvement 8

A working range of 50-250 ng/mL is more realistic 8, but therapeutic drug monitoring should not drive management in most cases.

Pruritus

Dosing for Pruritus

For uraemic pruritus in dialysis patients, use doxepin 10 mg twice daily 9. In one crossover study of 24 hemodialysis patients:

• 58% achieved complete resolution vs. 8% on placebo
• 29% had relative improvement vs. 17% on placebo
• 50% experienced drowsiness (dose-limiting) 9

Topical doxepin 5% cream is highly effective for histamine-induced pruritus, demonstrating superior antipruritic activity compared to diphenhydramine 10. This formulation minimizes systemic side effects while providing local H1-receptor blockade.

Contraindications

Absolute Contraindications

• Glaucoma: Doxepin can trigger angle-closure attack in patients with anatomically narrow angles without patent iridectomy 5
• Urinary retention: Anticholinergic effects worsen obstruction 5
• MAO inhibitor use: Must discontinue MAOIs at least 14 days before starting doxepin
• Hypersensitivity to doxepin or tricyclics

Relative Contraindications/Cautions

• Cardiac disease: Risk of arrhythmias, conduction abnormalities, hypotension, and tachycardia 5
• Respiratory compromise: COPD, asthma, sleep apnea—sedation may worsen hypoventilation 11
• Hepatic impairment: Reduce dose; doxepin undergoes extensive hepatic metabolism 5
• Renal impairment: Use caution; extent of renal excretion not fully determined 5
• Seizure disorders: Tricyclics lower seizure threshold 5
• Bipolar disorder: May precipitate manic/mixed episodes 5
• Pregnancy/nursing: Not recommended; apnea and drowsiness reported in nursing infant 5

Monitoring Parameters

Baseline Assessment

• ECG: Mandatory in patients >40 years or with cardiac risk factors; look for QRS prolongation, QTc prolongation 5
• Blood pressure: Establish baseline for orthostatic hypotension monitoring
• Liver function tests: Baseline AST/ALT
• Renal function: Creatinine, BUN
• Complete blood count: Baseline for hematologic monitoring
• Suicide risk assessment: Critical given black box warning 5

Ongoing Monitoring

First 4-8 weeks (critical period):

• Weekly visits to assess for suicidality, worsening depression, agitation, anxiety, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, or mania 5
• Monitor for anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision 5
• Assess orthostatic blood pressure
• Evaluate sedation/drowsiness (most common side effect) 5

Maintenance phase:

• Every 3 months: Clinical assessment, blood pressure, weight
• Every 6 months: CBC (watch for agranulocytosis, leukopenia, thrombocytopenia) 5
• Every 6 months: Liver function tests
• As needed: ECG if cardiac symptoms develop

Specific Monitoring for Elderly

Elderly patients require more intensive monitoring 5:

• Start at lower doses (see above)
• Monitor for confusion and oversedation
• Assess fall risk (sedation + orthostatic hypotension)
• Check for urinary retention (especially men with BPH)
• Monitor cognitive function

Discontinuation Monitoring

Taper doxepin over 10-14 days to prevent withdrawal symptoms including rebound insomnia, anxiety, and flu-like symptoms 6, 5. Abrupt cessation after prolonged use can cause significant withdrawal.

Critical Safety Warnings

Black Box Warning: Suicidality

Antidepressants increase suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder 5. Close monitoring is essential, particularly:

• During initial treatment months
• At dose changes (increases or decreases)
• When symptoms worsen or new symptoms emerge

Overdose Risk

Doxepin overdose is potentially fatal 5. Critical manifestations include:

• Cardiac dysrhythmias (QRS widening is key indicator)
• Severe hypotension
• Seizures
• CNS depression/coma

Prescribe the smallest quantity consistent with good management to reduce overdose risk 5.

Drug Interactions

• CNS depressants/alcohol: Additive sedation and psychomotor impairment 11, 5
• Anticholinergic drugs: Additive anticholinergic effects
• CYP2D6 inhibitors: May increase doxepin levels
• Avoid combining with other sedative-hypnotics unless specifically indicated

Common Pitfalls

1. Confusing insomnia and depression dosing: 3-6 mg for insomnia vs. 75-300 mg for depression—these are completely different therapeutic approaches
2. Using low-dose doxepin for insomnia in depressed patients: Ineffective; requires full antidepressant doses 4
3. Inadequate suicide monitoring: The black box warning demands vigilant early monitoring
4. Abrupt discontinuation: Always taper over 10-14 days
5. Ignoring cardiac screening: ECG is essential before starting, especially in older adults
6. Overlooking angle-closure glaucoma risk: Screen for narrow angles
7. Combining with alcohol or other sedatives: Dangerous additive effects